-
公开(公告)号：KR100291470B1
公开(公告)日：2001-11-26
申请号：KR1019980006065
申请日：1998-02-26
Applicant: 일양약품주식회사
Abstract: PURPOSE: A process of preparing an ipriflavone formulation by dissolving ipriflavone in a suitable solvent and then adding an additive capable of being used as an absorption accelerating agent(solubilizing aid) is provided. The ipriflavone tablet and capsule obtained by this process have excellent bioavailability and remarkably increases solubility of drugs. CONSTITUTION: Ipriflavone is dissolved using one or more mixtures selected from the group consisting of alcohols, acetone, dimethylsulfoxide, dimethylamide, tetrahydrofuran, acetonitrile, 1,4-dioxane, hexane, chloroform, methylenechloride, ether, ethylacetate, methylacetate or water. And then polyethylene glycol, a mixture of fatty acid ester and saturated polyglycol glyceride, sorbitan esters, polysorbates, propylene glycol, castor oil or polyoxyethylene castor oil derivatives alone or two or more mixtures are added to the solution as an absorption-accelerating agent. The mixture is spray-dried or freeze-dried and then added with an absorption-increasing agent.
-
公开(公告)号：KR1019990072826A
公开(公告)日：1999-09-27
申请号：KR1019990005822
申请日：1999-02-22
Applicant: 일양약품주식회사
IPC: A61K9/16
CPC classification number: A61K9/5026 , A61K9/1635 , A61K9/1652 , A61K9/2081 , A61K9/5042 , A61K9/5052 , A61K38/465 , A61K38/47 , A61K38/48 , A61K2300/00
Abstract: 본발명은판크레아틴을씨드(seed)로하여저온에서 1차코팅한다음, 필요에따라 2차코팅을실시하여타정압에안정하며장내효소활성이우수한판크레아틴장용코팅과립을제조하는방법에관한것이다.
-
-
-
5.发明公开2-[(4-메톡시-3-메틸)-2-피리디닐]메틸설피닐-5-(1Ｈ-피롤-1-릴)-1Ｈ-벤즈이미다졸 또는 이의 Ｎа염을 함유하는주사제의 제조방법 有权含有2 - [（4-甲氧基-3-甲基）-2-吡啶基]甲基吗啉-5-（1H-吡咯-1-基）-1H-苯并咪唑或其盐的注射溶液的生产
公开(公告)号：KR1020030075662A
公开(公告)日：2003-09-26
申请号：KR1020020015002
申请日：2002-03-20
Applicant: 일양약품주식회사
IPC: A61K31/4184
Abstract: PURPOSE: A process of preparing an injection solution stably containing IY-81149 while having no adverse effect by adjusting the pH of IY-81149 or Na salts thereof to 9 to 10 with an alkalinizing agent, freeze-drying it and then dissolving the obtained freeze dried product in an aqueous solvent is provided. Therefore, the product has no side effect such as hemolysis, local events or the like. CONSTITUTION: An injection solution is prepared by the steps of: (i)preparing a freeze dried product by adjusting the pH of 2-£(4-methoxy-3-methyl)-2-pyridinyl|methylsulfinyl-5-(1H-pyrrol-1-yl)-1H-benzimidazole or Na salt thereof with an inorganic or organic alkalinizing agent to 9.0 to 10.0 and freeze-drying; (ii)preparing a solvent for injection solution by adding a pharmaceutically acceptable additive to an aqueous solvent containing 0 to 50(w/v)% of a non-aqueous solvent. The inorganic or organic alkalinizing agent is selected from diethanolamine, triethanolamine, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate and a combination thereof.
Abstract translation: 目的：使用碱化剂将IY-81149或其盐的pH调节至9〜10，同时不会产生不利影响的方法制备稳定含有IY-81149的注射溶液，冷冻干燥，然后溶解所得冷冻 提供在水性溶剂中的干燥产物。 因此，该产品没有副作用，如溶血，局部事件等。 构成：通过以下步骤制备注射溶液：（i）通过调节2-（4-甲氧基-3-甲基）-2-吡啶基|甲基亚磺酰基-5-（1H-吡咯烷酮）的pH值来制备冷冻干燥产物 -1-基）-1H-苯并咪唑或其钠与无机或有机碱化剂反应至9.0至10.0并冷冻干燥; （ii）通过向含有0〜50（w / v）％的非水溶剂的水性溶剂中添加药学上可接受的添加剂来制备注射溶液的溶剂。 无机或有机碱化剂选自二乙醇胺，三乙醇胺，氢氧化钠，氢氧化钾，碳酸钠，碳酸钾及其组合。
-
Patent Agency Ranking6.发明授权
-
公开(公告)号：KR1020010010664A
公开(公告)日：2001-02-15
申请号：KR1019990029673
申请日：1999-07-21
Applicant: 일양약품주식회사
IPC: A61K9/70
CPC classification number: A61K9/7046 , A61K31/135 , A61K47/12
Abstract: PURPOSE: A plasta composition(a kind of subcutaneous administration system) for soothing itch is provided, which shows good adhesiveness and high absorption rate, is easy to separate, and solves problems of the secondary infection, stickiness of existing skin-administrating preparation. CONSTITUTION: A process for the preparation of plasta composition for soothing itch comprises the steps of: mixing and dissolving diphenhydramine(anti-histamine agent), dibucaine-HCl, and capric acid(absorption-promoting agent) in N-methylpyrolidone; adding the mixed solution into butylacrylate copolymer high-molecular solution(AS-594; a kind of adhesive agents); adding ethylacetate(dissolving adjuvant), mixing for 25minutes, and leaving for 20minutes to remove bubbles; spreading the mixture on a thin sheet in 50-150μ thick, and drying for 5minutes at 80deg.C to prepare drug-reservoir layer(the drug-reservoir layer can be prepared in the form of multi-layer structure); and applying a plastic film on the layer, and cutting into 3.14cm2 size to get the final product.
Abstract translation: 目的：提供舒缓瘙痒的plasta组合物（一种皮下给药系统），具有良好的粘附性和高吸收率，容易分离，并解决了二次感染，现有皮肤给药制剂的粘性问题。 构成：用于制备用于舒缓瘙痒的塑性组合物的方法包括以下步骤：将苯海拉明（抗组胺剂），地布卡宁-HCl和癸酸（吸收促进剂）混合并溶解在N-甲基吡咯烷酮中; 将混合溶液加入到丙烯酸丁酯共聚物高分子溶液（AS-594;一种粘合剂）中; 加入乙酸乙酯（溶解佐剂），混合25分钟，并留下20分钟以除去气泡; 将混合物铺在50-150μ厚的薄片上，在80℃下干燥5分钟，制备药物储层（药层可以以多层结构的形式制备）; 并在该层上涂一层塑料薄膜，切成3.14cm2尺寸以得到最终产品。
-
公开(公告)号：KR1020000024702A
公开(公告)日：2000-05-06
申请号：KR1019980041351
申请日：1998-10-01
Applicant: 일양약품주식회사
IPC: A61K9/70
CPC classification number: A61K9/7084 , A61K9/7092 , A61K31/192
Abstract: PURPOSE: A pasting agent containing anti-inflammatory analgesics composition like as Loxoprofen or its salts is provided, which makes prescription effect to be maximum by applying the effective medicine to the skin without causing gastroenteric trouble or peptic ulcer. The cata plasma also can release effective composition like as Loxoprofen or its salts continuously in a fixed amount. CONSTITUTION: A pasting agent containing anti-inflammatory analgesics composition comprises of 0.5-25wt.% of Loxoprofen or its salts, 25-80wt.% of adhesive polymer, 8-70wt.% of dissolving supplemental agent and 0.5-15wt.% of absorption accelerator. The pasting agent containing anti-inflammatory analgesics composition consists of a supporter(1), a removable layer(2) and single of multi layer(3) containing medicine in it.
Abstract translation: 目的：提供含有洛索洛芬或其盐类抗炎止痛剂组合物的粘贴剂，通过将有效药物施用于皮肤而不引起胃肠道疾病或消化性溃疡，使处方效果最大化。 气相等离子体还可以以固定的量连续释放如洛索丙芬或其盐类的有效组合物。 构成：含有消炎止痛剂组合物的糊剂包含0.5-25wt％的洛索丙芬或其盐，25-80wt。％的粘合剂聚合物，8-70wt。％的溶解补充剂和0.5-15wt。％的吸收 加速器。 含有消炎止痛剂组合物的糊剂由其中含有药物的支持体（1），可除去层（2）和单层多层（3）组成。
-
公开(公告)号：KR1019990070922A
公开(公告)日：1999-09-15
申请号：KR1019980006065
申请日：1998-02-26
Applicant: 일양약품주식회사
Abstract: 본 발명은 이프리플라본을 적당한 용매에 녹이고, 여기에 흡수촉진제(용해보조제)를 첨가하고, 이를 분무건조하거나 동결건조하여 입자화하고 흡수증가제를 가하는 단계를 포함함을 특징으로 하는 이프리플라본 정제 또는 캡슐제의 제조방법에 관한 것이다. 본 발명에 의해 제조된 정제 또는 캡슐제는 생체이용율이 우수하다.
-
公开(公告)号：KR1019960015954B1
公开(公告)日：1996-11-25
申请号：KR1019930009870
申请日：1993-06-02
Applicant: 일양약품주식회사
IPC: A61K33/06
Abstract: The therapeutic agent for gastric diseases is prepared by the steps of forming a paste by adding a corn starch in pure water at a ratio of 54:1080(w/w)(I); mixing 500mg almagate with 500mg dihydroxyaluminium sodium carbonate, re-mixing it with 860mg paste of(I), drying at 40-50deg.C, sieving the re-mixt. to obtain a white colored powder(II); mixing 20mg glycyrrhiza powder, 100mg Scopolia extract powder, 92mg cinnamon bark powder, 22mg orange peel powder, 15mg Korean genian powder, 12mg clove powder, 20mg mutmeg powder, and 24mg fennel powder, blending it with 200mg paste of (I), drying sufficiently at 40deg.C, and sieving it to obtain a brown colored powder(III); giving a pressure on 50mg biodiastase 2000 to make a box form and pulvelizing(IV); blending L-mentol with lactose at 1:60(V); finally mixing the above (II),(III),(IV), and (V) at a ratio of 1038:350:50:61 by weight homogeneously and packaging to obtain the final product.
Abstract translation: 通过以54:1080（w / w）（I）的比例在纯水中加入玉米淀粉来形成糊剂的步骤来制备胃疾病治疗剂; 将500mg铝酸钾与500mg二羟基碳酸钠混合，再与860mg（I）的糊剂混合，在40-50℃下干燥，筛分混合物。 得到白色粉末（II）; 混合20mg甘草粉，100mg Scopolia提取物粉末，92mg肉桂皮粉末，22mg橙皮粉末，15mg韩国根粉，12mg丁香粉，20mg肉粉粉末和24mg茴香粉，与200mg（I）糊剂混合，充分干燥 在40℃下进行筛分，得到棕色粉末（III）; 给予50mg生物活性酶2000的压力以制造盒形式和叶片（IV）; 以1:60（V）将L-薄荷醇与乳糖混合; 最终以1038:350:50:61的比例均匀地混合上述（II），（III），（IV）和（V），并包装以获得最终产物。
-
-
-
-
-
-
-
-
-
Search Results
38
records
(took 0.018 seconds)
